FOR AUTHORS
Search
Search Results
##search.searchResults.foundPlural##
-
OC-09 | Atogepant in treatment-refractory chronic migraine: is a revision of current criteria for refractory migraine appropriate? Lorenzo Tartaglione, Marcello Silvestro, Ilaria Orologio, Marcella Marziani, Francesco Maurizio Chianese, Pasquale Sozio, Alessandro Tessitore, Gioacchino Tedeschi, Antonio Russo | Headache Center, Department of Advanced Medical and Surgical Sciences (DAMSS), University of Campania "Luigi Vanvitelli", Naples, Italy
240 -
PO-21 | Evaluating the impact of anti-CGRP monoclonal antibodies on retinal features in migraine patients: a retrospective optical coherence tomography study Chiara Serafini,1 Massimo Cesareo,2 Alessio Martucci,2 Marco Lombardo,2 Vittoria Carla D’Agostino,1 Alessandro Stefani,3 Carlo Nucci,2 Nicola Biagio Mercuri,1,3 Maria Albanese1,3 | 1Regional Referral Headache Center, Neurology Unit, Tor Vergata University Hospital, Rome, Italy 2Ophthalmology Unit, Department of Experimental Medicine, University of Rome “Tor Vergata”, Rome; 3Department of Systems Medicine, University of Rome “Tor Vergata”, Rome, Italy
180 -
PO-77 | Real-world evidence of Atogepant efficacy in patients unresponsive to anti-CGRP monoclonals Matteo Cortinovis, Marco Bolchini, Paola Zavarise, Giulia Campana, Giorgio Dalla Volta | Headache Center, Istituto Clinico Città di Brescia, Gruppo San Donato, Brescia, Italy
186 -
OC-13 | Monoclonal antibodies targeting CGRP differently affect sleep and psychiatric comorbidities in reproductive and postmenopausal chronic migraine women Giulia Procopio, Letizia Curto, Antonia Di Chirico, Leonardo Troilo, Gabriele Siciliano, Filippo Baldacci, Sara Gori | Neurology Unit, Department of Clinical and Experimental Medicine, University of Pisa-AOUP, Pisa, Italy
247 -
PO-22 | Impact of sleep disorders on anti-CGRP monoclonal antibodies treatment response in migraine: a cross-sectional study Costanza Sottani,1 Valerio Brunetti,1,2 Fabiana Cerulli,1 Claudia Garattini,4 Gianluca Avino,5 Paolo Calabresi,1,3 Catello Vollono1,4 | 1Università Cattolica del Sacro Cuore, Dipartimento di Neuroscienze, Rome; 2Stroke Unit, Fondazione Policlinico Agostino Gemelli IRCSS, Rome; 3UOC Neurologia, Fondazione Policlinico Agostino Gemelli IRCSS, Rome; 4UOC Neurofisiopatologia, Fondazione Policlinico Agostino Gemelli IRCSS, Rome; 5Unità di Neurologia, Ospedale Santo Stefano, Prato, Italy
118 -
PO-78 | No changes in blood pressure assessed with the 24-hour Holter monitoring in patients treated with anti-CGRP monoclonal antibodies: a prospective observational study (SAFHYPER) Flavia Lo Castro,1 Niccolò Bonini,2 Luigi Francesco Iannone,1,3 Alberto Boccalini,1 Daria Brovia,1 Luca Pani,1,3 Giuseppe Boriani,2,3 Simona Guerzoni1 | 1Digital and Predictive Medicine, Pharmacology and Clinical Metabolic Toxicology-Headache Center and Drug Abuse-Laboratory of Clinical Pharmacology and Pharmacogenomics, AOU Policlinico di Modena, Modena, Italy; 2Cardiology Division, AOU Policlinico di Modena, Modena, Italy; 3Department of Biomedical, Metabolic, and Neural Science, University of Modena and Reggio Emilia, Modena, Italy
195 -
PO-86 | CGRP, VIP and PACAP plasmatic levels in migraine patients before and after anti-CGRP(R) monoclonal antibodies prophylaxis Alessia Bellotti,1 Davide Chiasserini,2 Alfredo Megaro,2 Daniela Fruttini,3 Pierluigi Navarra,4 Giuseppe Tringali,4 Paolo Calabresi,5 Lucilla Parnetti,1 Paola Sarchielli1 | 1Department of Medicine and Surgery, Section of Neurology, University of Perugia, Perugia, Italy; 2Department of Medicine and Surgery, Section of Physiology and Biochemistry, University of Perugia, Perugia, Italy; 3Department of Medicine and Surgery, Section of Internal Medicine, University of Perugia, Perugia, Italy; 4Department of Healthcare Surveillance and Bioethics, Section of Pharmacology, Catholic University Medical School, Fondazione Policlinico Universitario A. Gemelli-IRCCS, Rome, Italy; 5Department of Medicine and Surgery, Section of Neurology, Catholic University Medical School, Fondazione Policlinico Universitario A. Gemelli-IRCCS, Rome, Italy
196 -
PO-43 | Eptinezumab in migraine patients unresponsive to prior subcutaneous CGRP(-R) monoclonal antibody treatment: a retrospective case series Elena Cresta, Irene Mattioli, Michele Di Pasquale, Alice Lanfranchi, Renata Rao, Alessandro Padovani | Neurology Unit and Headache Centre, Dipartimento di continuità di cura e fragilità, ASST Spedali Civili e Università degli studi di Brescia, Brescia, Italy
161 -
PO-80 | Real-world effectiveness of atogepant for the preventive treatment of migraine in a cohort of multi -refractory patients: a single center study M. De Luca,1 L. Ferraù,1 A. Cafarchio,2 M.S. Adragna,1 M. Autunno1 | 1Unit of Neurology and Neuromuscular Diseases, Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy; 2Department of Medicine and Health Sciences “Vincenzo Tibero” DIMES, University of Molise, Campobasso, Italy
190 -
PO-52 | Long-term efficacy of CGRP mAbs: new insights and current evidence Oreste Marsico,1 Marta Lioi,2 Rosario Iannacchero,3 Michele Trimboli3 | 1Department of Neuroscience, “Giovanni Paolo II” Hospital, Lamezia Terme, Catanzaro, Italy; 2Department of Neurology, Magna Graecia University, Catanzaro, Italy; 3Institute of Neurology, AOU Renato Dulbecco, Catanzaro, Italy
81 -
PO-19 | Unraveling the spectrum of migraine resistant to treatments: searching for novel biological PHEnotypes and theRApeutic approaches (SPHERA project) M. Giraudo,1,2 R. De Icco,1,2 G. Vaghi,1,2 V. Grillo,1,2 F. Bighiani,1,2 M. Corrado,2 A. Antoniazzi,1,2 F. Cammarota,1,2 B. Agostini,1,2 A. Solfrizzi,1,2 M. Allena,2 E. Guaschino,2 N. Ghiotto,2 R. Greco,2 C. Demartini,2 A. Zanaboni,1,2 M. Francavilla,1,2 S. Facchetti,1,2 G. Sances,2 C. Tassorelli1,2 | 1Department of Brain and Behavioral Sciences, University of Pavia; 2Headache Science and Neurorehabilitation Unit, IRCCS Mondino Foundation, Pavia, Italy
169 -
OC-18 | Effectiveness of fremanezumab up to 12 months in different subgroups of participants: results from the Italian analysis of the PEARL study Raffaele Ornello,1 Gisella Airola,2 Letizia Curto,3 Diletta Alivernini,4 Chiara Abagnale,5 Pinar Kokturk,6 Yan Tereshko7 | 1Department of Biotechnological and Applied Clinical Sciences, University of L’Aquila; 2Department of Surgical Sciences, Women's Headache Center, University of Turin; 3Neurology Unit, Department of Clinical and Experimental Medicine, University of Pisa; 4Department of Neuroscience, Mental Health and Sensory Organs (NESMOS), Sapienza University of Rome; 5Department of Medico-Surgical Sciences and Biotechnologies, Sapienza University of Rome Polo Pontino ICOT, Latina, Italy; 6TEVA Pharmaceuticals Europe B.V., Haarlem, The Netherlands; 7Clinical Neurology, Department of Head-Neck and Neuroscience, Azienda Sanitaria Universitaria Friuli Centrale (ASU FC), Udine, Italy
77 -
PO-70 | A nomogram for the prediction of response to anti-CGRP mAbs: the CGRP score Marina Romozzi,1 Ammar Lokhandwala,2 Catello Vollono,1 David García-Azorín,3 Giulia Vigani,4 Francesco De Cesaris,4 Claudia Altamura,5 Fabrizio Vernieri,5 Paolo Calabresi,1 Sonia Di Tella,6 Luigi Francesco Iannone7 1Dipartimento Universitario di Neuroscienze, Università Cattolica del Sacro Cuore, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy; 2Drexel University, Philadelphia, PA, USA; 3Hospital Universitario del Río Hortega, Valladolid, Headache Unit, Department of Neurology, Valladolid, Spain; 4Section of Clinical Pharmacology and Oncology, Department of Health Sciences, University of Florence, Florence, Italy; 5 Neurologia, Dipartimento di Medicina e Chirurgia, Università Campus Bio-Medico di Roma, Rome, Italy; 6Dipartimento di Psicologia, Università Cattolica del Sacro Cuore, Milan, Italy; 7Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Modena, Italy
144 -
PO-57 | Early treatment with atogepant improves sleep quality without sleep-related adverse events: a prospective observational study Alberto Boccalini,1 Luigi Francesco Iannone,1,2* Flavia Lo Castro,1 Daria Brovia,1 Marina Romozzi,3,4 Fabrizio Vernieri,5,6 Claudia Altamura,5,6 Simona Guerzoni1 | 1Digital and Predictive Medicine, Pharmacology and Clinical Metabolic Toxicology-Headache Center and Drug Abuse-Laboratory of Clinical Pharmacology and Pharmacogenomics, AOU Policlinico di Modena, Modena, Italy; 2Department of Biomedical, Metabolic, and Neural Science, University of Modena and Reggio Emilia, Modena, Italy; 3Dipartimento Universitario di Neuroscienze, Università Cattolica del Sacro Cuore, Rome, Italy; 4Neurologia, Dipartimento di neuroscienze, Organi di Senso e Torace, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy; 5Headache Unit, Fondazione Policlinico Universitario Campus Bio-Medico, Roma, Italy; 6Università Campus Bio-Medico di Roma, Italy
106 -
PO-82 | Integrated approach with detoxification, CGRP monoclonal antibodies and psychoeducational support in two patients with complex medication overuse headache Claudia Lanni,1 Federica Papini,2 Chiara Prevost,3 Alessandro Canessa,3 Lucia Testa,3 Cristoforo Comi,2 Delfina Ferrandi3 | 1Department of Psychology “Santi Antonio e Biagio”, University Hospital, Alessandria, Italy; 2Neurology Unit, Department of Transitional Medicine, University of Piemonte Orientale, and University Hospital “Maggiore della Carità”, Novara, Italy; 3Neurology Unit, “Santi Antonio e Biagio” University Hospital, Alessandria, Italy
180 -
PO-56 | The role of bilateral greater occipital nerve block in resistant chronic migraine with medication overuse Leonardo Troilo, Letizia Curto, Giulia Procopio, Antonia Di Chirico, Gabriele Siciliano, Sara Gori, Filippo Baldacci | Neurology Unit, Department of Clinical and Experimental Medicine, University of Pisa-AOUP, Pisa, Italy
95
1 - 24 of 24 items